查看購物車
  • English
  • Japanese
  • Korean
全球下一代藥物偶聯物市場：按產品、類型、靶向配體、有效載荷類型、適應症和地區分類－預測至2035年
市場調查報告書
商品編碼
2027370

全球下一代藥物偶聯物市場：按產品、類型、靶向配體、有效載荷類型、適應症和地區分類－預測至2035年

Next Generation Drug Conjugates Market by Product (Enhertu, Amvuttra), Type (Antibody-Small Molecule), Target Ligand (Antibody, Peptide), Payload Type (Oligonucleotide, Radionuclide), Indication (Breast Cancer, Prostate Cancer) - Global Forecast to 2035
出版日期: | 出版商: MarketsandMarkets | 英文 331 Pages | 訂單完成後即時交付

價格

預計到 2035 年，下一代藥物偶聯物的全球市場規模將達到 425.5 億美元，而 2026 年為 157.5 億美元，預計在 2026 年至 2035 年的預測期內，複合年成長率將達到 11.7%。

預計在預測期內，全球下一代藥物偶聯物市場將實現強勁成長，這主要得益於標靶治療的日益普及、連接子、有效載荷和標靶化配體技術的不斷創新，以及對腫瘤藥物研發投入的增加。

調查範圍
調查期 2026-2035
基準年 2025
預測期 2026-2035
目標單元 金額（10億美元）
部分 ：
目標區域 北美、歐洲、亞太地區、拉丁美洲、中東和非洲

根據公開的行業資訊進行的市場預測顯示，到2034年，這些治療方法將保持強勁的兩位數成長，反映出其在臨床和商業上的發展勢頭。然而，安全隱患、生產流程的複雜性以及高昂的治療成本預計仍將是限制市場進一步擴張的主要因素。

下一代藥物偶聯物市場-IMG1

“在2025年的下一代藥物偶聯物市場中，Enhertu在單一產品中佔據最大的市場佔有率。”

從產品角度來看，新世代藥物偶聯物市場大致可分為 Enhartu（fam-trastuzumab deruxtecan-NXKI）、Pulvicto（lutetium Lu 177 vipivotide tetraxetan）、Ambutra（vutrisiran）、Trodelvi（saci​​alumabumabun​​alk-Mumabs、iumaba、iumab身） (HER3-DXd)、225Ac-PSMA-617、其他已上市產品以及其他在研發線產品。預計到 2025 年，Enhartu 板塊將佔據最大的市場佔有率。其主導地位歸功於多種因素，包括對多種 HER2 表達腫瘤類型具有顯著療效、適應症迅速擴展至轉移性乳癌以外的更廣泛固體癌領域，以及獨特的 DXd 有效載荷和旁觀者效應增強了醫生的信心並促進了治療方案的採納。此外，Enhertz 也受惠於全球市場滲透率的擴大、在治療早期階段使用量的增加，以及Astra Zeneca和第一三共強大的研發和商業化能力的大力支持。

“在2025年的下一代藥物偶聯物市場中，按類型分類，抗體-小分子藥物偶聯物細分市場將佔據最大的市場佔有率。”

從終端用戶的角度來看，全球下一代藥物偶聯物市場可細分為抗體-小分子藥物偶聯物、配體-寡核苷酸偶聯物、小分子-放射性同位素偶聯物、胜肽-放射性同位素偶聯物和其他類型的偶聯物。預計到2025年，抗體-小分子偶聯物將佔據最大的市場佔有率。這主要是因為抗體藥物複合體是目前臨床應用最廣泛、商業性程度最高的標靶偶聯物，持續的技術進步正在改善多種腫瘤的治療效果。

“預計從2026年到2035年，北美將在下一代藥物偶聯物市場中擁有最高的複合年成長率。”

下一代藥物偶聯物市場按地區分類為北美、歐洲、亞太、拉丁美洲以及中東和非洲。在預測期內，北美地區預計將以最高的複合年成長率成長。這一成長預計將受到該地區生物製藥創新集中度、先進標靶治療的早期應用以及諾華、輝瑞和Alnilam等主要市場參與企業積極開發和商業化下一代藥物偶聯物等因素的推動。

本報告涵蓋的公司簡介列表

  • Alnylam Pharmaceuticals
  • Gilead Sciences, Inc.
  • Novartis AG
  • AstraZeneca
  • Daiichi Sankyo Company, Limited
  • Ionis Pharmaceuticals, Inc.
  • Rakuten Group
  • Novo Nordisk
  • ADC Therapeutics SA
  • Sanofi
  • Arrowhead Pharmaceuticals
  • Abbvie
  • Regeneron Pharmaceuticals, Inc.
  • Bicycle therapeutics
  • Avidity Biosciences
  • Silence Therapeutics
  • MediLink Therapeutics
  • SystImmune, Inc.
  • Actinium Pharmaceuticals
  • Alphamab Oncology
  • Fusion Pharma
  • Orano group
  • PepGen Inc
  • Tubulis GmbH
  • Clarity Pharmaceuticals

調查範圍

本研究報告按產品、類型、標靶配體、有效載荷類型、適應症和地區分析了下一代藥物偶聯物市場。

本報告深入分析了影響下一代藥物偶聯物市場成長的關鍵因素，包括促進因素、挑戰、機會和限制因素。報告詳細分析了主要行業參與企業，深入剖析了他們的業務概況、產品系列、產品核准和上市情況、夥伴關係、業務擴張、協議以及與下一代藥物偶聯物市場相關的關鍵策略。此外，報告還對下一代藥物偶聯物市場生態系統中的主要參與者和新創公司進行了競爭分析。

購買本報告的主要好處

本報告透過提供下一代藥物偶聯物市場及其細分市場最準確的銷售預測，為市場領導和新參與企業提供幫助。它也有助於相關人員深入了解競爭格局，合理定位自身業務，並制定有效的打入市場策略。本報告使相關人員能夠掌握市場趨勢，並獲取有關關鍵市場促進因素、限制因素、機會和挑戰的資訊。

本報告深入分析了以下幾點：

  • 對關鍵促進因素（抗體藥物複合體的臨床成功率和監管核准不斷提高、連接子化學和有效載荷開發方面的技術進步）、阻礙因素（與複雜生物製藥相關的高昂開發和製造成本）、機遇（藥物偶聯物擴展到非腫瘤治療領域）和挑戰（複雜的臨床試驗設計和患者選擇要求）的分析正在影響下一代藥物偶聯物市場的新世代成長。
  • 產品開發/創新：對下一代藥物偶聯物市場新上市產品的詳細分析
  • 市場發展：盈利市場的全面資訊－本報告分析了各個地區的下一代藥物偶聯物市場。
  • 市場多元化：提供有關下一代藥物偶聯物市場的新產品、未開發地區、最新趨勢和投資的全面資訊。
  • 競爭分析：對下一代藥物偶聯物市場主要參與者的市場佔有率、成長策略和產品陣容進行詳細評估（包括 Alnylam Pharmaceuticals（美國）、Gilead Sciences, Inc.（美國）、Novartis AG（瑞士）、AstraZeneca（英國）、Daiichi Sankyo Company, Limited（日本）和 Ionis Pharmaceticals, Inc.（美國）。

目錄

第1章：引言

第2章執行摘要

第3章重要考察

第4章 市場概覽

  • 市場動態
    • 促進因素
    • 抑制因子
    • 機會
    • 任務
  • 未滿足的需求和未開發的領域
  • 相互關聯的市場與跨產業機遇
  • 參與企業一級/二級/三級市場的策略性舉措。

第5章 產業趨勢

  • 波特五力分析
  • 宏觀經濟展望
  • 價值鏈分析
  • 生態系分析
  • 價格分析
  • 重要會議和活動
  • 影響我們客戶公司業務的趨勢/變化
  • 投資及資金籌措活動
  • 美國關稅對下一代藥物複合物市場的影響

第6章：科技進步、人工智慧的影響、創新與未來應用

  • 技術分析
  • 技術/產品藍圖
  • 未來應用
  • 人工智慧/非專利人工智慧對下一代藥物複合物市場的影響
  • 管道分析

第7章：監理情勢與永續性舉措

  • 當地法規和合規性
  • 對永續性和監管政策舉措的影響

第8章：顧客趨勢與購買行為

  • 決策流程
  • 買方相關人員和採購評估標準
  • 實施障礙和內部挑戰
  • 最終用戶未被滿足的需求
  • 市場盈利

第9章：下一代藥物偶聯物市場（依產品分類）

  • 恩赫茲
  • 普爾維克托
  • 安布特拉
  • 特羅德爾比
  • 沙妥珠單抗
  • 帕特珠單抗德魯西替康
  • 225AC-PSMA-617
  • 其他市售產品
  • 其他研發線產品

第10章：下一代藥物偶聯物市場（按類型分類）

  • 抗體-小分子複合物
  • 胜肽-放射性核種複合物
  • 配體-寡核苷酸複合物
  • 其他

第11章：下一代藥物偶聯物市場（以標靶配體分類）

  • 抗體
  • 氨基糖
  • 低分子
  • 胜肽

第12章：下一代藥物偶聯物市場（按有效載荷類型分類）

  • 低分子量有效載荷
  • 寡核苷酸有效載荷
  • 放射性核種有效載荷

第13章：下一代藥物偶聯物市場（依適應症分類）

  • 乳癌
  • 伴隨神經病變的HATTR
  • 攝護腺癌
  • 原發性高血脂症
  • 其他

第14章：下一代藥物偶聯物市場（按地區分類）

  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 其他
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東
    • 海灣合作理事會國家
    • 其他
  • 非洲
    • 市場領先的研究合作與基礎建設

第15章 競爭格局

  • 概述
  • 主要參與企業的策略/優勢
  • 2021-2025年收入分析
  • 市佔率分析
  • 企業估值矩陣：主要公司，2025 年
  • 公司估值矩陣：新創企業/中小企業，2025 年
  • 企業估值和財務指標
  • 品牌對比
  • 競爭格局

第16章：公司簡介

  • 主要參與企業
    • ASTRAZENECA
    • DAIICHI SANKYO COMPANY, LIMITED
    • NOVARTIS AG
    • ALNYLAM PHARMACEUTICALS, INC
    • GILEAD SCIENCES, INC.
    • IONIS PHARMACEUTICALS, INC.
    • RAKUTEN GROUP, INC.
    • NOVO NORDISK
    • ADC THERAPEUTICS SA
    • SANOFI
    • ARROWHEAD PHARMACEUTICALS
    • ABBVIE INC.
    • REGENERON PHARMACEUTICALS INC.
  • 其他公司
    • BICYCLE THERAPEUTICS
    • AVIDITY BIOSCIENCES
    • SILENCE THERAPEUTICS
    • MEDILINK THERAPEUTICS
    • SYSTIMMUNE, INC.
    • ACTINIUM PHARMACEUTICALS
    • ALPHAMAB ONCOLOGY
    • FUSION PHARMA
    • ORANO GROUP
    • PEPGEN INC
    • TUBULIS GMBH
    • CLARITY PHARMACEUTICALS

第17章調查方法

第18章附錄

Product Code: PH 10413

The global next generation drug conjugates market is estimated to reach USD 42.55 billion by 2035 from USD 15.75 billion in 2026, at a CAGR of 11.7% during the forecast period of 2026 to 2035. The global next generation drug conjugates market is projected to witness strong growth over the forecast period, supported by rising adoption of targeted therapies, continued innovation in linker, payload, and targeting ligand technologies, and increasing investment in oncology-focused drug development.

Scope of the Report
Years Considered for the Study2026-2035
Base Year2025
Forecast Period2026-2035
Units ConsideredValue (USD billion)
SegmentsProduct, Type, Targeting ligand, Payload type, Indications
Regions coveredNorth America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa

Market estimates from published industry sources indicate robust double-digit growth through 2034, reflecting strong clinical and commercial momentum for these therapies. However, safety concerns, manufacturing complexity, and high treatment costs are expected to remain key factors restraining broader market expansion.

Next Generation Drug Conjugates Market - IMG1

"The Enhertu product segment accounted for the largest share by product in the next generation drug conjugates market in 2025."

Based on product, the next generation drug conjugates market is broadly segmented into Enhertu (fam-trastuzumab deruxtecan-nxki), Pluvicto (lutetium Lu 177 vipivotide tetraxetan), Amvuttra (vutrisiran), Trodelvy (sacituzumab govitecan-hziy), Sacituzumab tirumotecan, Patritumab Deruxtecan (HER3-DXd), 225Ac-PSMA-617, other commercialized products and other pipeline products. The ENHERTU segment held the largest market share in 2025. This leadership can be attributed to several factors, including its strong efficacy across multiple HER2-expressing tumor types, rapid label expansion beyond metastatic breast cancer into broader solid tumor settings, and its differentiated DXd payload and bystander effect, which have strengthened physician confidence and treatment adoption. In addition, Enhertu has benefited from growing global commercial penetration, increasing use in earlier lines of therapy, and strong backing from AstraZeneca and Daiichi Sankyo's extensive development and commercialization capabilities.

"The antibody-small molecule drug conjugate segment accounted for the largest share by type segment in the next generation drug conjugates market in 2025."

Based on end users, the global next generation drug conjugates market is segmented into antibody-small molecule drug conjugates, ligand-oligonucleotide conjugates, small molecule-radionuclide conjugates, peptide-radionuclide conjugates, and other conjugate types. In 2025, the antibody-small molecule segment accounted for the largest share of the market. This is primarily because antibody-drug conjugates are the most clinically established and commercially advanced class within targeted conjugates, with continued technological progress improving outcomes across multiple tumor types.

"North America is growing at the highest CAGR in the next generation drug conjugates market from 2026 to 2035."

The next generation drug conjugates market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East and Africa. During the forecast period, the North American region is estimated to grow at the highest CAGR. This growth is expected to be supported by the region's strong concentration of biopharmaceutical innovation, early adoption of advanced targeted therapies and the presence of key market participants, such as Novartis, Pfizer and Alnylam, actively developing and commercializing next generation drug conjugates.

The primary interviews conducted for this report can be categorized as follows:

  • By Respondent: Supply Side - 70% and Demand Side - 30%
  • By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%
  • By Designation: CXOs and Directors - 30%, Managers - 45%, and Others - 25%
  • By Region: North America - 40%, Europe - 25%, Asia Pacific - 20%, Latin America - 10%, and the Middle East - 5%

List of Companies Profiled in the Report

  • Alnylam Pharmaceuticals
  • Gilead Sciences, Inc.
  • Novartis AG
  • AstraZeneca
  • Daiichi Sankyo Company, Limited
  • Ionis Pharmaceuticals, Inc.
  • Rakuten Group
  • Novo Nordisk
  • ADC Therapeutics SA
  • Sanofi
  • Arrowhead Pharmaceuticals
  • Abbvie
  • Regeneron Pharmaceuticals, Inc.
  • Bicycle therapeutics
  • Avidity Biosciences
  • Silence Therapeutics
  • MediLink Therapeutics
  • SystImmune, Inc.
  • Actinium Pharmaceuticals
  • Alphamab Oncology
  • Fusion Pharma
  • Orano group
  • PepGen Inc
  • Tubulis GmbH
  • Clarity Pharmaceuticals

Research Coverage

This research report categorizes the next generation drug conjugates market by product (Enhertu [fam-trastuzumab deruxtecan-nxki], Pluvicto [lutetium Lu 177 vipivotide tetraxetan], AMVUTTRA [vutrisiran], TRODELVY [sacituzumab govitecan-hziy], Sacituzumab tirumotecan, Patritumab Deruxtecan [HER3-DXd], 225Ac-PSMA-617, other commercialized products and other pipeline products); by type: antibody-small molecule drug conjugate, ligand-oligonucleotide conjugate, small molecule-radionuclide conjugate, peptide-radionuclide conjugate, and other conjugate types; by targeting ligand: antibody, amino sugar, small molecule and peptide; by payload type: small molecule, oligonucleotide, and radionuclide; by indications: breast cancer, prostate cancer, hATTR with polyneuropathy, primary hyperlipidemia and other indications; and by region (North America, Europe, Asia Pacific, Latin America, Middle East, Africa).

The scope of the report covers detailed information regarding the major factors, such as drivers, challenges, opportunities, and restraints, influencing the growth of the next generation drug conjugates market. A detailed analysis of the key industry players has been done to provide insights into their business overview, product portfolio, key strategies such as product approvals and launches, collaborations, partnerships, expansions, agreements, and recent developments associated with the next generation drug conjugates market. Competitive analysis of top players and upcoming startups in the next generation drug conjugates market ecosystem is covered in this report.

Key Benefits of Buying the Report

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall next generation drug conjugates market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:

  • Analysis of key drivers (increasing clinical success and regulatory approvals of antibody-drug conjugates, technological advancements in linker chemistry and payload development), restraints (high development and manufacturing costs associated with complex biologics), opportunities (expansion of drug conjugates into non-oncology therapeutic areas) and challenges (complex clinical trial design and patient selection requirements) are influencing the growth of next generation drug conjugates market
  • Product Development/Innovation: Detailed insights on newly launched products of the next generation drug conjugates market
  • Market Development: Comprehensive information about lucrative markets - the report analyses the next generation drug conjugates market across varied regions
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the next generation drug conjugates market
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players include Alnylam Pharmaceuticals (US), Gilead Sciences, Inc. (US), Novartis AG (Switzerland), AstraZeneca (UK), Daiichi Sankyo Company, Limited (Japan), Ionis Pharmaceuticals, Inc. (US), among others in the next generation drug conjugates market

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED AND REGIONS CONSIDERED
    • 1.3.2 INCLUSIONS & EXCLUSIONS
    • 1.3.3 YEARS CONSIDERED
    • 1.3.4 CURRENCY CONSIDERED
  • 1.4 STAKEHOLDERS

2 EXECUTIVE SUMMARY

  • 2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS
  • 2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS
  • 2.3 DISRUPTIVE TRENDS SHAPING THE MARKET
  • 2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS
  • 2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST

3 PREMIUM INSIGHTS

  • 3.1 NEXT-GENERATION DRUG CONJUGATES MARKET OVERVIEW
  • 3.2 NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND & REGION
  • 3.3 NEXT-GENERATION DRUG CONJUGATES MARKET: GEOGRAPHIC SNAPSHOT

4 MARKET OVERVIEW

  • 4.1 INTRODUCTION
  • 4.2 MARKET DYNAMICS
    • 4.2.1 DRIVERS
      • 4.2.1.1 Increasing clinical success and regulatory approvals of antibody-drug conjugates
      • 4.2.1.2 Technological advancements in linker chemistry and payload development
    • 4.2.2 RESTRAINTS
      • 4.2.2.1 High development and manufacturing costs associated with complex biologics
    • 4.2.3 OPPORTUNITIES
      • 4.2.3.1 Expansion of drug conjugates into non-oncology therapeutic areas
      • 4.2.3.2 Increasing developments of novel conjugate platforms
    • 4.2.4 CHALLENGES
      • 4.2.4.1 Concerns related to biocompatibility, safety, and adverse immune responses
  • 4.3 UNMET NEEDS AND WHITE SPACES
  • 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
    • 4.4.1 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE
    • 4.4.2 PHARMACEUTICAL MANUFACTURING SERVICES MARKET FOR SMALL MOLECULES, BY TYPE
    • 4.4.3 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE
    • 4.4.4 BIOCONJUGATION SERVICES MARKET, BY CONJUGATION TYPE
  • 4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS

5 INDUSTRY TRENDS

  • 5.1 PORTER'S FIVE FORCES ANALYSIS
    • 5.1.1 THREAT OF NEW ENTRANTS
    • 5.1.2 THREAT OF SUBSTITUTES
    • 5.1.3 BARGAINING POWER OF BUYERS
    • 5.1.4 BARGAINING POWER OF SUPPLIERS
    • 5.1.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.2 MACROECONOMIC OUTLOOK
    • 5.2.1 INTRODUCTION
    • 5.2.2 GDP TRENDS AND FORECAST
    • 5.2.3 TRENDS IN GLOBAL NEXT-GENERATION DRUG CONJUGATES MARKET
  • 5.3 VALUE CHAIN ANALYSIS
  • 5.4 ECOSYSTEM ANALYSIS
  • 5.5 PRICING ANALYSIS
    • 5.5.1 INDICATIVE SELLING PRICE, BY KEY PLAYER, 2025 (USD)
    • 5.5.2 AVERAGE SELLING PRICE TREND, BY REGION, 2023-2025 (USD)
    • 5.5.3 AVERAGE SELLING PRICE RANGE, BY REGION, 2025 (USD)
  • 5.6 KEY CONFERENCES & EVENTS
  • 5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • 5.8 INVESTMENT & FUNDING ACTIVITY
  • 5.9 IMPACT OF US TARIFFS-NEXT-GENERATION DRUG CONJUGATES MARKET
    • 5.9.1 INTRODUCTION
    • 5.9.2 KEY TARIFF RATES
    • 5.9.3 PRICE IMPACT ANALYSIS
    • 5.9.4 IMPACT ON COUNTRIES/REGIONS
      • 5.9.4.1 North America
      • 5.9.4.2 Europe
      • 5.9.4.3 Asia Pacific
    • 5.9.5 IMPACT ON END-USE INDUSTRIES
      • 5.9.5.1 Hospitals
      • 5.9.5.2 Specialty clinics and cancer centers
      • 5.9.5.3 Other specialty care settings

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, INNOVATIONS, AND FUTURE APPLICATIONS

  • 6.1 TECHNOLOGY ANALYSIS
    • 6.1.1 KEY TECHNOLOGIES
      • 6.1.1.1 New-generation payload chemistries
      • 6.1.1.2 Radioligand/theranostic conjugate engineering
    • 6.1.2 ADJACENT TECHNOLOGIES
      • 6.1.2.1 Protein engineering/antibody engineering
    • 6.1.3 COMPLEMENTARY TECHNOLOGIES
      • 6.1.3.1 Diagnostic imaging/theranostics workflows
  • 6.2 TECHNOLOGY/PRODUCT ROADMAP
  • 6.3 FUTURE APPLICATIONS
  • 6.4 IMPACT OF AI/GEN AI ON NEXT-GENERATION DRUG CONJUGATES MARKET
    • 6.4.1 TOP USE CASES AND MARKET POTENTIAL
    • 6.4.2 CASE STUDIES OF AI IMPLEMENTATION IN NEXT-GENERATION DRUG CONJUGATES MARKET
    • 6.4.3 INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS
    • 6.4.4 CLIENTS' READINESS TO ADOPT GENERATIVE AI IN NEXT-GENERATION DRUG CONJUGATES MARKET
  • 6.5 PIPELINE ANALYSIS

7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES

  • 7.1 REGIONAL REGULATIONS AND COMPLIANCE
    • 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • 7.1.2 REGULATORY FRAMEWORK & REIMBURSEMENT
      • 7.1.2.1 Reimbursement scenario
    • 7.1.3 INDUSTRY STANDARDS
    • 7.1.4 CERTIFICATIONS, LABELING, AND ECO-STANDARDS
  • 7.2 SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES

8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR

  • 8.1 DECISION-MAKING PROCESS
  • 8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA
    • 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 8.2.2 KEY BUYING CRITERIA, BY END USER
  • 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
  • 8.4 UNMET NEEDS FROM END USERS
  • 8.5 MARKET PROFITABILITY

9 NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT

  • 9.1 INTRODUCTION
  • 9.2 ENHERTU
    • 9.2.1 BROAD CLINICAL ADOPTION AND REGULATORY EXPANSION OF TARGETED ADC THERAPIES DRIVE MARKET GROWTH
  • 9.3 PLUVICTO
    • 9.3.1 EXPANDING USE OF TARGETED RADIOLIGAND THERAPY IN PROSTATE CANCER TO DRIVE MARKET GROWTH
  • 9.4 AMVUTTRA
    • 9.4.1 ADVANCING RNAI THERAPEUTICS THROUGH DURABLE GENE SILENCING AND EXPANDED INDICATION REACH
  • 9.5 TRODELVY
    • 9.5.1 RISING GOVERNMENT APPROVALS FOR BREAST CANCER TREATMENTS TO DRIVE MARKET GROWTH
  • 9.6 SACITUZUMAB TIRUMOTECAN
    • 9.6.1 ADVANCING NEXT-GENERATION ADC PAYLOAD INNOVATION IN NDC MARKET
  • 9.7 PATRITUMAB DERUXTECAN
    • 9.7.1 ADVANCEMENTS IN HER3-DIRECTED ANTIBODY-DRUG CONJUGATES TO AID GROWTH
  • 9.8 225AC-PSMA-617
    • 9.8.1 POTENT THERAPEUTIC PROFILE AND EXPANDING CLINICAL VALIDATION TO SUPPORT MARKET GROWTH
  • 9.9 OTHER COMMERCIALIZED PRODUCTS
  • 9.10 OTHER PIPELINE PRODUCTS

10 NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE

  • 10.1 INTRODUCTION
  • 10.2 ANTIBODY-SMALL MOLECULE CONJUGATES
    • 10.2.1 ENHANCED CLINICAL UTILITY AND TECHNOLOGICAL INNOVATION TO DRIVE MARKET
  • 10.3 PEPTIDE-RADIONUCLIDE CONJUGATES
    • 10.3.1 INNOVATIONS IN PRECISION ONCOLOGY APPLICATIONS AND TECHNOLOGICAL ADVANCEMENTS SUPPORT GROWTH
  • 10.4 LIGAND-OLIGONUCLEOTIDE CONJUGATES
    • 10.4.1 ENHANCED DELIVERY AND TISSUE TARGETING CAPABILITIES OF LIGAND-OLIGONUCLEOTIDE CONJUGATES DRIVE GROWTH
  • 10.5 OTHER DRUG CONJUGATES

11 NEXT-GENERATION DRUG MARKET, BY TARGET LIGAND

  • 11.1 INTRODUCTION
  • 11.2 ANTIBODIES
    • 11.2.1 ADVANCEMENTS IN ANTIBODY ENGINEERING AND EXPANDING TARGET DIVERSITY DRIVE GROWTH
  • 11.3 AMINO SUGARS
    • 11.3.1 GROWING ADOPTION OF GALNAC-BASED LIVER-TARGETING PLATFORMS DRIVES EXPANSION
  • 11.4 SMALL MOLECULES
    • 11.4.1 EXPANDING USE OF SMALL-MOLECULE TARGETING LIGANDS IS BROADENING THE NEXT-GENERATION DRUG CONJUGATES MARKET
  • 11.5 PEPTIDES
    • 11.5.1 EXPANDING CLINICAL PIPELINES AND TUMOR-TARGETING INNOVATIONS PROPEL GROWTH

12 NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE

  • 12.1 INTRODUCTION
  • 12.2 SMALL-MOLECULE PAYLOADS
    • 12.2.1 RISING ADOPTION OF HIGHLY POTENT, NEXT-GENERATION PAYLOADS AND ADVANCED LINKER TECHNOLOGIES IS ACCELERATING GROWTH
  • 12.3 OLIGONUCLEOTIDE PAYLOADS
    • 12.3.1 RISING ADOPTION OF RNA-BASED GENE-SILENCING THERAPIES AND LONG-ACTING CONJUGATE PLATFORMS TO DRIVE MARKET
  • 12.4 RADIONUCLIDE PAYLOADS
    • 12.4.1 EXPANDING RADIOLIGAND THERAPY ADOPTION AND ADVANCEMENTS IN ISOTOPE TECHNOLOGIES SUPPORT MARKET GROWTH

13 NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION

  • 13.1 INTRODUCTION
  • 13.2 BREAST CANCER
    • 13.2.1 RISING INCIDENCE AND INCREASING ADOPTION OF TARGETED ADC THERAPIES TO DRIVE MARKET
  • 13.3 HATTR WITH POLYNEUROPATHY
    • 13.3.1 ADVANCEMENTS IN RNA-BASED GENE-SILENCING THERAPIES AND INCREASING DIAGNOSIS RATES ARE DRIVING GROWTH
  • 13.4 PROSTATE CANCER
    • 13.4.1 EXPANDING ADOPTION OF PSMA-TARGETED RADIOLIGAND THERAPIES IS DRIVING GROWTH
  • 13.5 PRIMARY HYPERLIPIDEMIA
    • 13.5.1 INCREASING ADOPTION OF LONG-ACTING RNA-BASED THERAPIES DRIVES MARKET GROWTH
  • 13.6 OTHER INDICATIONS

14 NEXT-GENERATION DRUG CONJUGATES MARKET, BY REGION

  • 14.1 INTRODUCTION
  • 14.2 NORTH AMERICA
    • 14.2.1 US
      • 14.2.1.1 FDA approvals, expanding clinical pipelines, and strategic collaborations drive market
    • 14.2.2 CANADA
      • 14.2.2.1 Increasing access to innovative NDC therapies drives growth
  • 14.3 EUROPE
    • 14.3.1 GERMANY
      • 14.3.1.1 Access to innovative therapies and strong radioligand infrastructure are driving growth
    • 14.3.2 UK
      • 14.3.2.1 Rising demand for precision oncology and advanced conjugate technologies drives market expansion
    • 14.3.3 FRANCE
      • 14.3.3.1 Biopharma presence and global innovation in targeted conjugates support market growth
    • 14.3.4 ITALY
      • 14.3.4.1 Expanding clinical research to accelerate market growth
    • 14.3.5 SPAIN
      • 14.3.5.1 Increased focus on research for NDC development to propel market growth
    • 14.3.6 REST OF EUROPE
  • 14.4 ASIA PACIFIC
    • 14.4.1 CHINA
      • 14.4.1.1 Strong domestic innovation and expanding oncology demand drive NDC market growth
    • 14.4.2 JAPAN
      • 14.4.2.1 Growing drug approvals and pharma biotech research initiatives support market growth
    • 14.4.3 INDIA
      • 14.4.3.1 Expanding biologics capabilities and rising demand for targeted oncology therapies support growth
    • 14.4.4 SOUTH KOREA
      • 14.4.4.1 Key drug approvals relevant to NDC market to aid growth in South Korea
    • 14.4.5 AUSTRALIA
      • 14.4.5.1 Strong regulatory framework, clinical innovation, and global partnerships drive market growth
    • 14.4.6 REST OF ASIA PACIFIC
  • 14.5 LATIN AMERICA
    • 14.5.1 BRAZIL
      • 14.5.1.1 Expanding clinical trials and rising demand for targeted oncology therapies drive market growth
    • 14.5.2 MEXICO
      • 14.5.2.1 Gradual increase in pharmaceutical R&D to support market growth
    • 14.5.3 REST OF LATIN AMERICA
  • 14.6 MIDDLE EAST
    • 14.6.1 GCC COUNTRIES
      • 14.6.1.1 Integration of genomics, biomarker-driven diagnostics, and personalized treatment to propel market
    • 14.6.2 REST OF MIDDLE EAST
  • 14.7 AFRICA
    • 14.7.1 RESEARCH COLLABORATIONS AND INFRASTRUCTURAL DEVELOPMENT TO DRIVE MARKET

15 COMPETITIVE LANDSCAPE

  • 15.1 OVERVIEW
  • 15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 15.3 REVENUE ANALYSIS, 2021-2025
  • 15.4 MARKET SHARE ANALYSIS
  • 15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
    • 15.5.1 STARS
    • 15.5.2 EMERGING LEADERS
    • 15.5.3 PERVASIVE PLAYERS
    • 15.5.4 PARTICIPANTS
    • 15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
      • 15.5.5.1 Company footprint
      • 15.5.5.2 Region footprint
      • 15.5.5.3 Type footprint
      • 15.5.5.4 Indication footprint
  • 15.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
    • 15.6.1 PROGRESSIVE COMPANIES
    • 15.6.2 RESPONSIVE COMPANIES
    • 15.6.3 DYNAMIC COMPANIES
    • 15.6.4 STARTING BLOCKS
    • 15.6.5 COMPETITIVE BENCHMARKING OF STARTUPS/SMES
      • 15.6.5.1 Detailed list of key startups/SMEs
  • 15.7 COMPANY VALUATION AND FINANCIAL METRICS
  • 15.8 BRAND COMPARISON
  • 15.9 COMPETITIVE SCENARIO
    • 15.9.1 PRODUCT APPROVALS
    • 15.9.2 DEALS
    • 15.9.3 EXPANSIONS

16 COMPANY PROFILES

  • 16.1 KEY PLAYERS
    • 16.1.1 ASTRAZENECA
      • 16.1.1.1 Business overview
      • 16.1.1.2 Products offered
      • 16.1.1.3 Recent developments
        • 16.1.1.3.1 Product approvals
        • 16.1.1.3.2 Deals
        • 16.1.1.3.3 Expansions
      • 16.1.1.4 MnM view
        • 16.1.1.4.1 Key strengths/Right to win
        • 16.1.1.4.2 Strategic choices made
        • 16.1.1.4.3 Weaknesses and competitive threats
    • 16.1.2 DAIICHI SANKYO COMPANY, LIMITED
      • 16.1.2.1 Business overview
      • 16.1.2.2 Products offered
      • 16.1.2.3 Products in pipeline
      • 16.1.2.4 Recent developments
        • 16.1.2.4.1 Product approvals
        • 16.1.2.4.2 Expansions
      • 16.1.2.5 MnM view
        • 16.1.2.5.1 Key strengths/Right to win
        • 16.1.2.5.2 Strategic choices made
        • 16.1.2.5.3 Weaknesses and competitive threats
    • 16.1.3 NOVARTIS AG
      • 16.1.3.1 Business overview
      • 16.1.3.2 Products offered
      • 16.1.3.3 Recent developments
        • 16.1.3.3.1 Product approvals
        • 16.1.3.3.2 Deals
        • 16.1.3.3.3 Expansions
      • 16.1.3.4 MnM view
        • 16.1.3.4.1 Key strengths/Right to win
        • 16.1.3.4.2 Strategic choices made
        • 16.1.3.4.3 Weaknesses and competitive threats
    • 16.1.4 ALNYLAM PHARMACEUTICALS, INC
      • 16.1.4.1 Business overview
      • 16.1.4.2 Products offered
      • 16.1.4.3 Recent developments
        • 16.1.4.3.1 Product approvals
        • 16.1.4.3.2 Deals
        • 16.1.4.3.3 Expansions
      • 16.1.4.4 MnM view
        • 16.1.4.4.1 Key strengths/Right to win
        • 16.1.4.4.2 Strategic choices made
        • 16.1.4.4.3 Weaknesses and competitive threats
    • 16.1.5 GILEAD SCIENCES, INC.
      • 16.1.5.1 Business overview
      • 16.1.5.2 Products offered
      • 16.1.5.3 Recent developments
        • 16.1.5.3.1 Deals
        • 16.1.5.3.2 Expansions
      • 16.1.5.4 MnM view
        • 16.1.5.4.1 Key strengths/Right to win
        • 16.1.5.4.2 Strategic choices made
        • 16.1.5.4.3 Weaknesses and competitive threats
    • 16.1.6 IONIS PHARMACEUTICALS, INC.
      • 16.1.6.1 Business overview
      • 16.1.6.2 Products offered
      • 16.1.6.3 Products in pipeline
      • 16.1.6.4 Recent developments
        • 16.1.6.4.1 Product approvals
        • 16.1.6.4.2 Deals
    • 16.1.7 RAKUTEN GROUP, INC.
      • 16.1.7.1 Business overview
      • 16.1.7.2 Products in pipeline
      • 16.1.7.3 Recent developments
        • 16.1.7.3.1 Deals
    • 16.1.8 NOVO NORDISK
      • 16.1.8.1 Business overview
      • 16.1.8.2 Products offered
      • 16.1.8.3 Recent developments
        • 16.1.8.3.1 Product approvals
        • 16.1.8.3.2 Deals
    • 16.1.9 ADC THERAPEUTICS SA
      • 16.1.9.1 Business overview
      • 16.1.9.2 Products offered
      • 16.1.9.3 Products in pipeline
    • 16.1.10 SANOFI
      • 16.1.10.1 Business overview
      • 16.1.10.2 Products offered
      • 16.1.10.3 Products in pipeline
      • 16.1.10.4 Recent developments
        • 16.1.10.4.1 Deals
    • 16.1.11 ARROWHEAD PHARMACEUTICALS
      • 16.1.11.1 Business overview
      • 16.1.11.2 Products offered
      • 16.1.11.3 Recent developments
        • 16.1.11.3.1 Product approvals
    • 16.1.12 ABBVIE INC.
      • 16.1.12.1 Business overview
      • 16.1.12.2 Products in pipeline
    • 16.1.13 REGENERON PHARMACEUTICALS INC.
      • 16.1.13.1 Business overview
      • 16.1.13.2 Products in pipeline
  • 16.2 OTHER PLAYERS
    • 16.2.1 BICYCLE THERAPEUTICS
    • 16.2.2 AVIDITY BIOSCIENCES
    • 16.2.3 SILENCE THERAPEUTICS
    • 16.2.4 MEDILINK THERAPEUTICS
    • 16.2.5 SYSTIMMUNE, INC.
    • 16.2.6 ACTINIUM PHARMACEUTICALS
    • 16.2.7 ALPHAMAB ONCOLOGY
    • 16.2.8 FUSION PHARMA
    • 16.2.9 ORANO GROUP
    • 16.2.10 PEPGEN INC
    • 16.2.11 TUBULIS GMBH
    • 16.2.12 CLARITY PHARMACEUTICALS

17 RESEARCH METHODOLOGY

  • 17.1 RESEARCH DATA
    • 17.1.1 SECONDARY DATA
    • 17.1.2 PRIMARY DATA
  • 17.2 MARKET ESTIMATION METHODOLOGY
    • 17.2.1 MARKET SIZE ESTIMATION
    • 17.2.2 INSIGHTS OF PRIMARY EXPERTS
    • 17.2.3 TOP-DOWN APPROACH
  • 17.3 MARKET GROWTH RATE PROJECTIONS
  • 17.4 MARKET BREAKDOWN AND DATA TRIANGULATION
  • 17.5 RESEARCH ASSUMPTIONS
  • 17.6 RESEARCH LIMITATIONS
  • 17.7 RISK ANALYSIS

18 APPENDIX

  • 18.1 DISCUSSION GUIDE
  • 18.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 18.3 CUSTOMIZATION OPTIONS
  • 18.4 RELATED REPORTS
  • 18.5 AUTHOR DETAILS

List of Tables

  • TABLE 1 NEXT-GENERATION DRUG CONJUGATES MARKET: IMPACT ANALYSIS
  • TABLE 2 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023-2030 (USD BILLION)
  • TABLE 3 PHARMACEUTICAL MANUFACTURING SERVICES MARKET FOR SMALL MOLECULES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 4 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023-2030 (USD BILLION)
  • TABLE 5 BIOCONJUGATION SERVICES MARKET, BY CONJUGATION TYPE, 2022-2029 (USD MILLION)
  • TABLE 6 NEXT-GENERATION DRUG CONJUGATES MARKET: PORTER'S FIVE FORCES ANALYSIS
  • TABLE 7 NEXT-GENERATION DRUG CONJUGATES MARKET: ROLE IN ECOSYSTEM
  • TABLE 8 INDICATIVE SELLING PRICE OF PRODUCTS, BY KEY PLAYER, 2025 (USD)
  • TABLE 9 AVERAGE SELLING PRICE TREND, BY REGION, 2023-2025 (USD)
  • TABLE 10 AVERAGE SELLING PRICE RANGE, BY REGION, 2025 (USD)
  • TABLE 11 NEXT-GENERATION DRUG CONJUGATES MARKET: KEY CONFERENCES & EVENTS, 2026-2027
  • TABLE 12 US-ADJUSTED RECIPROCAL TARIFF RATES
  • TABLE 13 CASE STUDIES OF AI IMPLEMENTATION IN NEXT-GENERATION DRUG CONJUGATES MARKET
  • TABLE 14 CLIENT'S READINESS TO ADOPT GENERATIVE AI
  • TABLE 15 KEY PIPELINE PRODUCTS IN NEXT-GENERATION DRUG CONJUGATES MARKET (AS OF MARCH 2026)
  • TABLE 16 EXAMPLES OF US REGULATORY PATHWAY, BY TYPE OF DRUG CONJUGATE
  • TABLE 17 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 18 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 19 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 20 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 21 REIMBURSEMENT STATUS AND TYPE, BY COUNTRY
  • TABLE 22 COUNTRY-WISE REGULATORY SCENARIO FOR NEXT-GENERATION DRUG CONJUGATE MANUFACTURERS
  • TABLE 23 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TYPE (%)
  • TABLE 24 KEY BUYING CRITERIA, BY END USER
  • TABLE 25 NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024-2035 (USD MILLION)
  • TABLE 26 NEXT-GENERATION DRUG CONJUGATES MARKET FOR ENHERTU, BY REGION, 2024-2035 (USD MILLION)
  • TABLE 27 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR ENHERTU, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 28 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR ENHERTU, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 29 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR ENHERTU, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 30 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR ENHERTU, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 31 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR ENHERTU, BY REGION, 2024-2035 (USD MILLION)
  • TABLE 32 NEXT-GENERATION DRUG CONJUGATES MARKET FOR PLUVICTO, BY REGION, 2024-2035 (USD MILLION)
  • TABLE 33 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PLUVICTO, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 34 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PLUVICTO, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 35 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PLUVICTO, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 36 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PLUVICTO , BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 37 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PLUVICTO, BY REGION, 2024-2035 (USD MILLION)
  • TABLE 38 NEXT-GENERATION DRUG CONJUGATES MARKET FOR AMVUTTRA, BY REGION, 2024-2035 (USD MILLION)
  • TABLE 39 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR AMVUTTRA, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 40 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR AMVUTTRA, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 41 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR AMVUTTRA, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 42 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR AMVUTTRA, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 43 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR AMVUTTRA, BY REGION, 2024-2035 (USD MILLION)
  • TABLE 44 NEXT-GENERATION DRUG CONJUGATES MARKET FOR TRODELVY, BY REGION, 2024-2035 (USD MILLION)
  • TABLE 45 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR TRODELVY, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 46 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR TRODELVY, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 47 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR TRODELVY, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 48 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR TRODELVY, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 49 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR TRODELVY, BY REGION, 2024-2035 (USD MILLION)
  • TABLE 50 NEXT-GENERATION DRUG CONJUGATES MARKET FOR SACITUZUMAB TIRUMOTECAN, BY REGION, 2024-2035 (USD MILLION)
  • TABLE 51 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SACITUZUMAB TIRUMOTECAN, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 52 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SACITUZUMAB TIRUMOTECAN, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 53 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SACITUZUMAB TIRUMOTECAN, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 54 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SACITUZUMAB TIRUMOTECAN, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 55 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SACITUZUMAB TIRUMOTECAN, BY REGION, 2024-2035 (USD MILLION)
  • TABLE 56 NEXT-GENERATION DRUG CONJUGATES MARKET FOR PATRITUMAB DERUXTECAN, BY REGION, 2024-2035 (USD MILLION)
  • TABLE 57 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PATRITUMAB DERUXTECAN, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 58 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PATRITUMAB DERUXTECAN, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 59 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PATRITUMAB DERUXTECAN, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 60 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PATRITUMAB DERUXTECAN, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 61 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PATRITUMAB DERUXTECAN, BY REGION, 2024-2035 (USD MILLION)
  • TABLE 62 NEXT-GENERATION DRUG CONJUGATES MARKET FOR 225AC-PSMA-617, BY REGION, 2024-2035 (USD MILLION)
  • TABLE 63 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR 225AC-PSMA-617, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 64 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR 225AC-PSMA-617, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 65 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR 225AC-PSMA-617, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 66 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR 225AC-PSMA-617, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 67 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR 225AC-PSMA-617, BY REGION, 2024-2035 (USD MILLION)
  • TABLE 68 NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER COMMERCIALIZED PRODUCTS, BY REGION, 2024-2035 (USD MILLION)
  • TABLE 69 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER COMMERCIALIZED PRODUCTS, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 70 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER COMMERCIALIZED PRODUCTS, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 71 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER COMMERCIALIZED PRODUCTS, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 72 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER COMMERCIALIZED PRODUCTS, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 73 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER COMMERCIALIZED PRODUCTS, BY REGION, 2024-2035 (USD MILLION)
  • TABLE 74 NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER PIPELINE PRODUCTS, BY REGION, 2024-2035 (USD MILLION)
  • TABLE 75 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER PIPELINE PRODUCTS, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 76 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER PIPELINE PRODUCTS, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 77 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER PIPELINE PRODUCTS, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 78 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER PIPELINE PRODUCTS, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 79 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER PIPELINE PRODUCTS, BY REGION, 2024-2035 (USD MILLION)
  • TABLE 80 NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024-2035 (USD MILLION)
  • TABLE 81 ANTIBODY-SMALL MOLECULE CONJUGATES MARKET, BY REGION, 2024-2035 (USD MILLION)
  • TABLE 82 NORTH AMERICA: ANTIBODY-SMALL MOLECULE CONJUGATES MARKET, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 83 EUROPE: ANTIBODY-SMALL MOLECULE CONJUGATES MARKET, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 84 ASIA PACIFIC: ANTIBODY-SMALL MOLECULE CONJUGATES MARKET, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 85 LATIN AMERICA: ANTIBODY-SMALL MOLECULE CONJUGATES MARKET, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 86 MIDDLE EAST: ANTIBODY-SMALL MOLECULE CONJUGATES MARKET, BY REGION, 2024-2035 (USD MILLION)
  • TABLE 87 PEPTIDE-RADIONUCLIDE CONJUGATES MARKET, BY REGION, 2024-2035 (USD MILLION)
  • TABLE 88 NORTH AMERICA: PEPTIDE-RADIONUCLIDE CONJUGATES MARKET, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 89 EUROPE: PEPTIDE-RADIONUCLIDE CONJUGATES MARKET, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 90 ASIA PACIFIC: PEPTIDE-RADIONUCLIDE CONJUGATES MARKET, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 91 LATIN AMERICA: PEPTIDE-RADIONUCLIDE CONJUGATES MARKET, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 92 MIDDLE EAST: PEPTIDE-RADIONUCLIDE CONJUGATES MARKET, BY REGION, 2024-2035 (USD MILLION)
  • TABLE 93 LIGAND-OLIGONUCLEOTIDE CONJUGATES MARKET, BY REGION, 2024-2035 (USD MILLION)
  • TABLE 94 NORTH AMERICA: LIGAND-OLIGONUCLEOTIDE CONJUGATES MARKET, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 95 EUROPE: LIGAND-OLIGONUCLEOTIDE CONJUGATES MARKET, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 96 ASIA PACIFIC: LIGAND-OLIGONUCLEOTIDE CONJUGATES MARKET, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 97 LATIN AMERICA: LIGAND-OLIGONUCLEOTIDE CONJUGATES MARKET, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 98 MIDDLE EAST: LIGAND-OLIGONUCLEOTIDE CONJUGATES MARKET, BY REGION, 2024-2035 (USD MILLION)
  • TABLE 99 OTHER NEXT-GENERATION DRUG CONJUGATES MARKET, BY REGION, 2024-2035 (USD MILLION)
  • TABLE 100 NORTH AMERICA: OTHER NEXT-GENERATION DRUG CONJUGATES MARKET, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 101 EUROPE: OTHER NEXT-GENERATION DRUG CONJUGATES MARKET, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 102 ASIA PACIFIC: OTHER NEXT-GENERATION DRUG CONJUGATES MARKET, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 103 LATIN AMERICA: OTHER NEXT-GENERATION DRUG CONJUGATES MARKET, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 104 MIDDLE EAST: OTHER NEXT-GENERATION DRUG CONJUGATES MARKET, BY REGION, 2024-2035 (USD MILLION)
  • TABLE 105 NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024-2035 (USD MILLION)
  • TABLE 106 NEXT-GENERATION DRUG CONJUGATES MARKET FOR ANTIBODIES, BY REGION, 2024-2035 (USD MILLION)
  • TABLE 107 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR ANTIBODIES, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 108 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR ANTIBODIES, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 109 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR ANTIBODIES, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 110 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR ANTIBODIES, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 111 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR ANTIBODIES, BY REGION, 2024-2035 (USD MILLION)
  • TABLE 112 NEXT-GENERATION DRUG CONJUGATES MARKET FOR AMINO SUGARS, BY REGION, 2024-2035 (USD MILLION)
  • TABLE 113 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR AMINO SUGARS, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 114 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR AMINO SUGARS, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 115 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR AMINO SUGARS, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 116 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR AMINO SUGARS, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 117 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR AMINO SUGARS, BY REGION, 2024-2035 (USD MILLION)
  • TABLE 118 NEXT-GENERATION DRUG CONJUGATES MARKET FOR SMALL MOLECULES, BY REGION, 2024-2035 (USD MILLION)
  • TABLE 119 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 120 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 121 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 122 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 123 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SMALL MOLECULES, BY REGION, 2024-2035 (USD MILLION)
  • TABLE 124 NEXT-GENERATION DRUG CONJUGATES MARKET FOR PEPTIDES, BY REGION, 2024-2035 (USD MILLION)
  • TABLE 125 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PEPTIDES, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 126 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PEPTIDES, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 127 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PEPTIDES, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 128 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PEPTIDES, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 129 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PEPTIDES, BY REGION, 2024-2035 (USD MILLION)
  • TABLE 130 NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024-2035 (USD MILLION)
  • TABLE 131 NEXT-GENERATION DRUG CONJUGATES MARKET FOR SMALL-MOLECULE PAYLOADS, BY REGION, 2024-2035 (USD MILLION)
  • TABLE 132 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SMALL-MOLECULE PAYLOADS, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 133 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SMALL-MOLECULE PAYLOADS, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 134 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SMALL-MOLECULE PAYLOADS, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 135 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SMALL-MOLECULE PAYLOADS, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 136 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SMALL-MOLECULE PAYLOADS, BY REGION, 2024-2035 (USD MILLION)
  • TABLE 137 NEXT-GENERATION DRUG CONJUGATES MARKET FOR OLIGONUCLEOTIDE PAYLOADS, BY REGION, 2024-2035 (USD MILLION)
  • TABLE 138 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OLIGONUCLEOTIDE PAYLOADS, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 139 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OLIGONUCLEOTIDE PAYLOADS, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 140 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OLIGONUCLEOTIDE PAYLOADS, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 141 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OLIGONUCLEOTIDE PAYLOADS, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 142 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OLIGONUCLEOTIDE PAYLOADS, BY REGION, 2024-2035 (USD MILLION)
  • TABLE 143 NEXT-GENERATION DRUG CONJUGATES MARKET FOR RADIONUCLIDE PAYLOADS, BY REGION, 2024-2035 (USD MILLION)
  • TABLE 144 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR RADIONUCLIDE PAYLOADS, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 145 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR RADIONUCLIDE PAYLOADS, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 146 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR RADIONUCLIDE PAYLOADS, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 147 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR RADIONUCLIDE PAYLOADS, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 148 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR RADIONUCLIDE PAYLOADS, BY REGION, 2024-2035 (USD MILLION)
  • TABLE 149 NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024-2035 (USD MILLION)
  • TABLE 150 NEXT-GENERATION DRUG CONJUGATES MARKET FOR BREAST CANCER, BY REGION, 2024-2035 (USD MILLION)
  • TABLE 151 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR BREAST CANCER, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 152 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR BREAST CANCER, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 153 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR BREAST CANCER, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 154 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR BREAST CANCER, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 155 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR BREAST CANCER, BY REGION, 2024-2035 (USD MILLION)
  • TABLE 156 NEXT-GENERATION DRUG CONJUGATES MARKET FOR HATTR WITH POLYNEUROPATHY, BY REGION, 2024-2035 (USD MILLION)
  • TABLE 157 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR HATTR WITH POLYNEUROPATHY, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 158 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR HATTR WITH POLYNEUROPATHY, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 159 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR HATTR WITH POLYNEUROPATHY, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 160 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR HATTR WITH POLYNEUROPATHY, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 161 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR HATTR WITH POLYNEUROPATHY, BY REGION, 2024-2035 (USD MILLION)
  • TABLE 162 NEXT-GENERATION DRUG CONJUGATES MARKET FOR PROSTATE CANCER, BY REGION, 2024-2035 (USD MILLION)
  • TABLE 163 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PROSTATE CANCER, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 164 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PROSTATE CANCER, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 165 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PROSTATE CANCER, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 166 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PROSTATE CANCER, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 167 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PROSTATE CANCER, BY REGION, 2024-2035 (USD MILLION)
  • TABLE 168 NEXT-GENERATION DRUG CONJUGATES MARKET FOR PRIMARY HYPERLIPIDEMIA, BY REGION, 2024-2035 (USD MILLION)
  • TABLE 169 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PRIMARY HYPERLIPIDEMIA, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 170 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PRIMARY HYPERLIPIDEMIA, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 171 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PRIMARY HYPERLIPIDEMIA, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 172 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PRIMARY HYPERLIPIDEMIA, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 173 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PRIMARY HYPERLIPIDEMIA, BY REGION, 2024-2035 (USD MILLION)
  • TABLE 174 NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER INDICATIONS, BY REGION, 2024-2035 (USD MILLION)
  • TABLE 175 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 176 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 177 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 178 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 179 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER INDICATIONS, BY REGION, 2024-2035 (USD MILLION)
  • TABLE 180 NEXT-GENERATION DRUG CONJUGATES MARKET, BY REGION, 2024-2035 (USD MILLION)
  • TABLE 181 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 182 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024-2035 (USD MILLION)
  • TABLE 183 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024-2035 (USD MILLION)
  • TABLE 184 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024-2035 (USD MILLION)
  • TABLE 185 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024-2035 (USD MILLION)
  • TABLE 186 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024-2035 (USD MILLION)
  • TABLE 187 US: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024-2035 (USD MILLION)
  • TABLE 188 US: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024-2035 (USD MILLION)
  • TABLE 189 US: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024-2035 (USD MILLION)
  • TABLE 190 US: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024-2035 (USD MILLION)
  • TABLE 191 US: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024-2035 (USD MILLION)
  • TABLE 192 CANADA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024-2035 (USD MILLION)
  • TABLE 193 CANADA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024-2035 (USD MILLION)
  • TABLE 194 CANADA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024-2035 (USD MILLION)
  • TABLE 195 CANADA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024-2035 (USD MILLION)
  • TABLE 196 CANADA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024-2035 (USD MILLION)
  • TABLE 197 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 198 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024-2035 (USD MILLION)
  • TABLE 199 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024-2035 (USD MILLION)
  • TABLE 200 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024-2035 (USD MILLION)
  • TABLE 201 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024-2035 (USD MILLION)
  • TABLE 202 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024-2035 (USD MILLION)
  • TABLE 203 GERMANY: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024-2035 (USD MILLION)
  • TABLE 204 GERMANY: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024-2035 (USD MILLION)
  • TABLE 205 GERMANY: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024-2035 (USD MILLION)
  • TABLE 206 GERMANY: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024-2035 (USD MILLION)
  • TABLE 207 GERMANY: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024-2035 (USD MILLION)
  • TABLE 208 UK: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024-2035 (USD MILLION)
  • TABLE 209 UK: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024-2035 (USD MILLION)
  • TABLE 210 UK: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024-2035 (USD MILLION)
  • TABLE 211 UK: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024-2035 (USD MILLION)
  • TABLE 212 UK: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024-2035 (USD MILLION)
  • TABLE 213 FRANCE: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024-2035 (USD MILLION)
  • TABLE 214 FRANCE: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024-2035 (USD MILLION)
  • TABLE 215 FRANCE: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024-2035 (USD MILLION)
  • TABLE 216 FRANCE: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024-2035 (USD MILLION)
  • TABLE 217 FRANCE: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024-2035 (USD MILLION)
  • TABLE 218 ITALY: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024-2035 (USD MILLION)
  • TABLE 219 ITALY: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024-2035 (USD MILLION)
  • TABLE 220 ITALY: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024-2035 (USD MILLION)
  • TABLE 221 ITALY: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024-2035 (USD MILLION)
  • TABLE 222 ITALY: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024-2035 (USD MILLION)
  • TABLE 223 SPAIN: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024-2035 (USD MILLION)
  • TABLE 224 SPAIN: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024-2035 (USD MILLION)
  • TABLE 225 SPAIN: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024-2035 (USD MILLION)
  • TABLE 226 SPAIN: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024-2035 (USD MILLION)
  • TABLE 227 SPAIN: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024-2035 (USD MILLION)
  • TABLE 228 REST OF EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024-2035 (USD MILLION)
  • TABLE 229 REST OF EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024-2035 (USD MILLION)
  • TABLE 230 REST OF EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024-2035 (USD MILLION)
  • TABLE 231 REST OF EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024-2035 (USD MILLION)
  • TABLE 232 REST OF EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024-2035 (USD MILLION)
  • TABLE 233 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 234 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024-2035 (USD MILLION)
  • TABLE 235 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024-2035 (USD MILLION)
  • TABLE 236 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024-2035 (USD MILLION)
  • TABLE 237 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024-2035 (USD MILLION)
  • TABLE 238 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024-2035 (USD MILLION)
  • TABLE 239 CHINA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024-2035 (USD MILLION)
  • TABLE 240 CHINA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024-2035 (USD MILLION)
  • TABLE 241 CHINA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024-2035 (USD MILLION)
  • TABLE 242 CHINA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024-2035 (USD MILLION)
  • TABLE 243 CHINA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024-2035 (USD MILLION)
  • TABLE 244 JAPAN: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024-2035 (USD MILLION)
  • TABLE 245 JAPAN: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024-2035 (USD MILLION)
  • TABLE 246 JAPAN: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024-2035 (USD MILLION)
  • TABLE 247 JAPAN: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024-2035 (USD MILLION)
  • TABLE 248 JAPAN: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024-2035 (USD MILLION)
  • TABLE 249 INDIA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024-2035 (USD MILLION)
  • TABLE 250 INDIA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024-2035 (USD MILLION)
  • TABLE 251 INDIA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024-2035 (USD MILLION)
  • TABLE 252 INDIA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024-2035 (USD MILLION)
  • TABLE 253 INDIA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024-2035 (USD MILLION)
  • TABLE 254 SOUTH KOREA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024-2035 (USD MILLION)
  • TABLE 255 SOUTH KOREA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024-2035 (USD MILLION)
  • TABLE 256 SOUTH KOREA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024-2035 (USD MILLION)
  • TABLE 257 SOUTH KOREA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024-2035 (USD MILLION)
  • TABLE 258 SOUTH KOREA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024-2035 (USD MILLION)
  • TABLE 259 AUSTRALIA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024-2035 (USD MILLION)
  • TABLE 260 AUSTRALIA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024-2035 (USD MILLION)
  • TABLE 261 AUSTRALIA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024-2035 (USD MILLION)
  • TABLE 262 AUSTRALIA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024-2035 (USD MILLION)
  • TABLE 263 AUSTRALIA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024-2035 (USD MILLION)
  • TABLE 264 REST OF ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024-2035 (USD MILLION)
  • TABLE 265 REST OF ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024-2035 (USD MILLION)
  • TABLE 266 REST OF ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024-2035 (USD MILLION)
  • TABLE 267 REST OF ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024-2035 (USD MILLION)
  • TABLE 268 REST OF ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024-2035 (USD MILLION)
  • TABLE 269 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY COUNTRY, 2024-2035 (USD MILLION)
  • TABLE 270 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024-2035 (USD MILLION)
  • TABLE 271 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024-2035 (USD MILLION)
  • TABLE 272 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024-2035 (USD MILLION)
  • TABLE 273 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024-2035 (USD MILLION)
  • TABLE 274 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024-2035 (USD MILLION)
  • TABLE 275 BRAZIL: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024-2035 (USD MILLION)
  • TABLE 276 BRAZIL: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024-2035 (USD MILLION)
  • TABLE 277 BRAZIL: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024-2035 (USD MILLION)
  • TABLE 278 BRAZIL: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024-2035 (USD MILLION)
  • TABLE 279 BRAZIL: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024-2035 (USD MILLION)
  • TABLE 280 MEXICO: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024-2035 (USD MILLION)
  • TABLE 281 MEXICO: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024-2035 (USD MILLION)
  • TABLE 282 MEXICO: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024-2035 (USD MILLION)
  • TABLE 283 MEXICO: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024-2035 (USD MILLION)
  • TABLE 284 MEXICO: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024-2035 (USD MILLION)
  • TABLE 285 REST OF LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024-2035 (USD MILLION)
  • TABLE 286 REST OF LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024-2035 (USD MILLION)
  • TABLE 287 REST OF LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024-2035 (USD MILLION)
  • TABLE 288 REST OF LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024-2035 (USD MILLION)
  • TABLE 289 REST OF LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024-2035 (USD MILLION)
  • TABLE 290 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET, BY REGION, 2024-2035 (USD MILLION)
  • TABLE 291 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024-2035 (USD MILLION)
  • TABLE 292 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024-2035 (USD MILLION)
  • TABLE 293 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024-2035 (USD MILLION)
  • TABLE 294 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024-2035 (USD MILLION)
  • TABLE 295 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024-2035 (USD MILLION)
  • TABLE 296 GCC COUNTRIES: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024-2035 (USD MILLION)
  • TABLE 297 GCC COUNTRIES: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024-2035 (USD MILLION)
  • TABLE 298 GCC COUNTRIES: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024-2035 (USD MILLION)
  • TABLE 299 GCC COUNTRIES: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024-2035 (USD MILLION)
  • TABLE 300 GCC COUNTRIES: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024-2035 (USD MILLION)
  • TABLE 301 REST OF MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024-2035 (USD MILLION)
  • TABLE 302 REST OF MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024-2035 (USD MILLION)
  • TABLE 303 REST OF MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024-2035 (USD MILLION)
  • TABLE 304 REST OF MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024-2035 (USD MILLION)
  • TABLE 305 REST OF MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024-2035 (USD MILLION)
  • TABLE 306 AFRICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024-2035 (USD MILLION)
  • TABLE 307 AFRICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024-2035 (USD MILLION)
  • TABLE 308 AFRICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024-2035 (USD MILLION)
  • TABLE 309 AFRICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024-2035 (USD MILLION)
  • TABLE 310 AFRICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024-2035 (USD MILLION)
  • TABLE 311 STRATEGIES ADOPTED BY KEY PLAYERS IN NEXT-GENERATION DRUG CONJUGATES MARKET, 2023-2026
  • TABLE 312 NEXT-GENERATION DRUG CONJUGATES MARKET: DEGREE OF COMPETITION
  • TABLE 313 NEXT-GENERATION DRUG CONJUGATES MARKET: REGION FOOTPRINT
  • TABLE 314 NEXT-GENERATION DRUG CONJUGATES MARKET: TYPE FOOTPRINT
  • TABLE 315 NEXT-GENERATION DRUG CONJUGATES MARKET: INDICATION FOOTPRINT
  • TABLE 316 NEXT-GENERATION DRUG CONJUGATES MARKET: KEY STARTUPS/SMES
  • TABLE 317 NEXT-GENERATION DRUG CONJUGATES MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
  • TABLE 318 NEXT-GENERATION DRUG CONJUGATES MARKET: PRODUCT APPROVALS, JANUARY 2023 TO MARCH 2026
  • TABLE 319 NEXT-GENERATION DRUG CONJUGATES MARKET: DEALS, JANUARY 2023 TO MARCH 2026
  • TABLE 320 NEXT-GENERATION DRUG CONJUGATES MARKET: EXPANSIONS, JANUARY 2023 TO MARCH 2026
  • TABLE 321 ASTRAZENECA: COMPANY OVERVIEW
  • TABLE 322 ASTRAZENECA: PRODUCTS OFFERED
  • TABLE 323 ASTRAZENECA: PRODUCT APPROVALS, JANUARY 2023- MARCH 2026
  • TABLE 324 ASTRAZENECA: DEALS, JANUARY 2023-MARCH 2026
  • TABLE 325 ASTRAZENECA: EXPANSIONS, JANUARY 2023-MARCH 2026
  • TABLE 326 DAIICHI SANKYO COMPANY, LIMITED: COMPANY OVERVIEW
  • TABLE 327 DAIICHI SANKYO COMPANY, LIMITED: PRODUCTS OFFERED
  • TABLE 328 DAIICHI SANKYO COMPANY, LIMITED: PRODUCTS IN PIPELINE
  • TABLE 329 DAIICHI SANKYO COMPANY, LIMITED: PRODUCT APPROVALS, JANUARY 2023-MARCH 2026
  • TABLE 330 DAIICHI SANKYO COMPANY, LIMITED: EXPANSIONS, JANUARY 2023-MARCH 2026
  • TABLE 331 NOVARTIS AG: COMPANY OVERVIEW
  • TABLE 332 NOVARTIS AG: PRODUCTS OFFERED
  • TABLE 333 NOVARTIS AG: PRODUCT APPROVALS, JANUARY 2023-MARCH 2026
  • TABLE 334 NOVARTIS AG: DEALS, JANUARY 2023-MARCH 2026
  • TABLE 335 NOVARTIS AG: EXPANSIONS, JANUARY 2023-MARCH 2026
  • TABLE 336 ALNYLAM PHARMACEUTICALS, INC.: COMPANY OVERVIEW
  • TABLE 337 ALNYLAM PHARMACEUTICALS, INC.: PRODUCTS OFFERED
  • TABLE 338 ALNYLAM PHARMACEUTICALS, INC.: PRODUCT APPROVALS, JANUARY 2023-MARCH 2026
  • TABLE 339 ALNYLAM PHARMACEUTICALS, INC.: DEALS, JANUARY 2023-MARCH 2026
  • TABLE 340 ALNYLAM PHARMACEUTICALS INC.: EXPANSIONS, JANUARY 2023-MARCH 2026
  • TABLE 341 GILEAD SCIENCES, INC.: COMPANY OVERVIEW
  • TABLE 342 GILEAD SCIENCES, INC.: PRODUCTS OFFERED
  • TABLE 343 GILEAD SCIENCES, INC.: DEALS, JANUARY 2023-MARCH 2026
  • TABLE 344 GILEAD SCIENCES, INC.: EXPANSIONS, JANUARY 2023-MARCH 2026
  • TABLE 345 IONIS PHARMACEUTICALS, INC.: COMPANY OVERVIEW
  • TABLE 346 IONIS PHARMACEUTICALS, INC.: PRODUCTS OFFERED
  • TABLE 347 IONIS PHARMACEUTICALS, INC.: PRODUCTS IN PIPELINE
  • TABLE 348 IONIS PHARMACEUTICALS, INC.: PRODUCT APPROVALS, JANUARY 2023-MARCH 2026
  • TABLE 349 IONIS PHARMACEUTICALS, INC.: DEALS, JANUARY 2023-MARCH 2026
  • TABLE 350 RAKUTEN GROUP, INC.: COMPANY OVERVIEW
  • TABLE 351 RAKUTEN GROUP, INC.: PRODUCTS IN PIPELINE
  • TABLE 352 RAKUTEN GROUP, INC.: DEALS, JANUARY 2023-MARCH 2026
  • TABLE 353 NOVO NORDISK: COMPANY OVERVIEW
  • TABLE 354 NOVO NORDISK: PRODUCTS OFFERED
  • TABLE 355 NOVO NORDISK: PRODUCT APPROVALS, JANUARY 2023-MARCH 2026
  • TABLE 356 NOVO NORDISK: DEALS, JANUARY 2023-MARCH 2026
  • TABLE 357 ADC THERAPEUTICS SA: COMPANY OVERVIEW
  • TABLE 358 ADC THERAPEUTICS SA: PRODUCTS OFFERED
  • TABLE 359 ADC THERAPEUTICS SA: PRODUCTS IN PIPELINE
  • TABLE 360 SANOFI: COMPANY OVERVIEW
  • TABLE 361 SANOFI: PRODUCTS OFFERED
  • TABLE 362 SANOFI: PRODUCTS IN PIPELINE
  • TABLE 363 SANOFI: DEALS, JANUARY 2023-MARCH 2026
  • TABLE 364 ARROWHEAD PHARMACEUTICALS: COMPANY OVERVIEW
  • TABLE 365 ARROWHEAD PHARMACEUTICALS: PIPELINE PRODUCTS
  • TABLE 366 ARROWHEAD PHARMACEUTICALS: PRODUCT APPROVALS, JANUARY 2023-MARCH 2026
  • TABLE 367 ABBVIE INC.: COMPANY OVERVIEW
  • TABLE 368 ABBVIE INC.: PRODUCTS IN PIPELINE
  • TABLE 369 REGENERON PHARMACEUTICALS: COMPANY OVERVIEW
  • TABLE 370 REGENERON PHARMACEUTICALS INC.: PRODUCTS IN PIPELINE
  • TABLE 371 BICYCLE THERAPEUTICS: COMPANY OVERVIEW
  • TABLE 372 AVIDITY BIOSCIENCES: COMPANY OVERVIEW
  • TABLE 373 SILENCE THERAPEUTICS: COMPANY OVERVIEW
  • TABLE 374 MEDILINK THERAPEUTICS: COMPANY OVERVIEW
  • TABLE 375 SYSTIMMUNE, INC.: COMPANY OVERVIEW
  • TABLE 376 ACTINIUM PHARMACEUTICALS: COMPANY OVERVIEW
  • TABLE 377 ALPHAMAB ONCOLOGY: COMPANY OVERVIEW
  • TABLE 378 FUSION PHARMA: COMPANY OVERVIEW
  • TABLE 379 ORANO GROUP: COMPANY OVERVIEW
  • TABLE 380 PEPGEN INC.: COMPANY OVERVIEW
  • TABLE 381 TUBULIS GMBH: COMPANY OVERVIEW
  • TABLE 382 CLARITY PHARMACEUTICALS: COMPANY OVERVIEW
  • TABLE 383 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS

List of Figures

  • FIGURE 1 MARKET SCENARIO
  • FIGURE 2 GLOBAL NEXT-GENERATION DRUG CONJUGATES MARKET, 2024-2035
  • FIGURE 3 MAJOR STRATEGIES ADOPTED BY KEY MARKET PLAYERS, 2023-2026
  • FIGURE 4 DISRUPTIONS INFLUENCING GROWTH OF NEXT-GENERATION DRUG CONJUGATES MARKET
  • FIGURE 5 HIGH-GROWTH SEGMENTS IN NEXT-GENERATION DRUG CONJUGATES MARKET, 2026-2035
  • FIGURE 6 NORTH AMERICA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD
  • FIGURE 7 TECHNOLOGICAL ADVANCEMENTS IN LINKER CHEMISTRY AND PAYLOAD DEVELOPMENT TO DRIVE GROWTH
  • FIGURE 8 ANTIBODY SEGMENT IN NORTH AMERICA ACCOUNTED FOR LARGEST MARKET SHARE IN 2025
  • FIGURE 9 CHINA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
  • FIGURE 10 NEXT-GENERATION DRUG CONJUGATES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 11 NEXT-GENERATION DRUG CONJUGATES MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 12 NEXT-GENERATION DRUG CONJUGATES MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 13 NEXT-GENERATION DRUG CONJUGATES MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 14 INDICATIVE SELLING PRICE OF PRODUCTS, BY KEY PLAYER, 2025 (USD)
  • FIGURE 15 INDICATIVE SELLING PRICE, BY REGION, 2025 (USD)
  • FIGURE 16 NEXT-GENERATION DRUG CONJUGATES MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • FIGURE 17 VC/PRIVATE EQUITY INVESTMENT TRENDS & STARTUP LANDSCAPE
  • FIGURE 18 IMPACT OF AI/GEN AI ON NEXT-GENERATION DRUG CONJUGATES MARKET
  • FIGURE 19 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TYPE
  • FIGURE 20 KEY BUYING CRITERIA, BY END USER
  • FIGURE 21 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET SNAPSHOT
  • FIGURE 22 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET SNAPSHOT
  • FIGURE 23 REVENUE ANALYSIS OF KEY PLAYERS, 2021-2025 (USD MILLION)
  • FIGURE 24 MARKET SHARE ANALYSIS OF KEY PLAYERS (2025)
  • FIGURE 25 NEXT-GENERATION DRUG CONJUGATES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
  • FIGURE 26 NEXT-GENERATION DRUG CONJUGATES MARKET: COMPANY FOOTPRINT
  • FIGURE 27 NEXT-GENERATION DRUG CONJUGATES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
  • FIGURE 28 EV/EBITDA OF KEY VENDORS
  • FIGURE 29 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 30 NEXT-GENERATION DRUG CONJUGATES MARKET: BRAND COMPARATIVE ANALYSIS
  • FIGURE 31 ASTRAZENECA: COMPANY SNAPSHOT (2025)
  • FIGURE 32 DAIICHI SANKYO COMPANY, LIMITED: COMPANY SNAPSHOT (2024)
  • FIGURE 33 NOVARTIS AG: COMPANY SNAPSHOT (2025)
  • FIGURE 34 ALNYLAM PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2025)
  • FIGURE 35 GILEAD SCIENCES, INC.: COMPANY SNAPSHOT (2025)
  • FIGURE 36 IONIS PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 37 RAKUTEN GROUP, INC.: COMPANY SNAPSHOT (2025)
  • FIGURE 38 NOVO NORDISK: COMPANY SNAPSHOT (2025)
  • FIGURE 39 ADC THERAPEUTICS SA: COMPANY SNAPSHOT (2025)
  • FIGURE 40 SANOFI: COMPANY SNAPSHOT (2025)
  • FIGURE 41 ARROWHEAD PHARMACEUTICALS: COMPANY SNAPSHOT (2025)
  • FIGURE 42 RESEARCH DESIGN
  • FIGURE 43 NEXT-GENERATION DRUG CONJUGATES MARKET: BREAKDOWN OF PRIMARIES
  • FIGURE 44 NEXT-GENERATION DRUG CONJUGATES MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2025
  • FIGURE 45 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2025
  • FIGURE 46 REVENUE SHARE ANALYSIS: ILLUSTRATIVE EXAMPLE OF ALNYLAM PHARMACEUTICALS (2025)
  • FIGURE 47 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
  • FIGURE 48 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  • FIGURE 49 NEXT-GENERATION DRUG CONJUGATES MARKET CAGR PROJECTIONS
  • FIGURE 50 DATA TRIANGULATION METHODOLOGY